Why the study?
Does long-term autoimmune diabetes enhance in-stent restenosis after aortic stenting in a rat model?
Does long-term autoimmune diabetes enhance in-stent restenosis after aortic stenting in a rat model?
Long-term autoimmune diabetes in BBDP rats enhances in-stent restenosis, providing a relevant animal model for studying pathogenetic mechanisms and testing new therapies.
Provides a relevant rat model for diabetic restenosis mechanisms; leaves open translation to human stent outcomes.
Type 1 diabetic patients have increased risk of developing in-stent restenosis following endovascular stenting. Underlying pathogenetic mechanisms are not fully understood partly due to the lack of a relevant animal model to study the effect(s) of long-term autoimmune diabetes on development of in-stent restenosis. We here describe the development of in-stent restenosis in long-term (~7 months) spontaneously diabetic and age-matched, thymectomized, nondiabetic Diabetes Prone BioBreeding (BBDP) rats (n = 6-7 in each group). Diabetes was suboptimally treated with insulin and was characterized by significant hyperglycaemia, polyuria, proteinuria, and increased HbA(1c) levels. Stented abdominal aortas were harvested 28 days after stenting. Computerized morphometric analysis revealed significantly increased neointima formation in long-term diabetic rats compared with nondiabetic controls. In conclusion, long-term autoimmune diabetes in BBDP rats enhances in-stent restenosis. This model can be used to study the underlying pathogenetic mechanisms of diabetes-enhanced in-stent restenosis as well as to test new therapeutic modalities.
No takes yet. Share an insight, caveat, or question.
Onuta et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: